Featured Research

from universities, journals, and other organizations

New drug candidate starves dormant cancer cells

Date:
February 18, 2014
Source:
Karolinska Institutet
Summary:
In solid tumors larger than a few millimetres, there is usually a lack of both oxygen and nutrients due to insufficient blood vessel growth. This in turn results in cancer cells falling into a state of dormancy. After treatment, such dormant cells will start to divide and tumors will grow. A new drug candidate selectively kills dormant cells within a cancer tumor through starvation. These tumor cells, which are found in less oxygenated parts of solid tumors, are resistant to conventional treatments.

In a study published in Nature Communications, researchers at Karolinska Institutet and Uppsala University in Sweden present a new drug candidate, which selectively kills dormant cells within a cancer tumour through starvation. These tumour cells, which are found in less oxygenated parts of solid tumours, are resistant to conventional treatments.

In solid tumours larger than a few millimetres, there is usually a lack of both oxygen and nutrients due to insufficient blood vessel growth. This in turn results in cancer cells falling into a state of dormancy. After treatment, such dormant cells will start to divide and tumours will grow. This phenomenon therefore contributes to resistance of solid tumour to radio- and chemotherapy.

In their newly published study, the researchers show that cancer cells located in tumour regions that are poorly oxygenated and lack nutrition are unable to compensate for deficient mitochondrial energy production.

"We have identified a small molecule that we call VLX600, which in various in vitro and in vivo models has proven effective against dormant colon cancer cells that are otherwise very difficult to treat. VLX600 is a mild inhibitor of mitochondrial respiration, and we have found that dormant cancer cells have a limited possibility to compensate decreased mitochondrial function by increased glycolysis. The dormant cancer cells therefore die by starvation" says Stig Linder, the professor of experimental oncology leading the study.

The VLX600 molecule has been developed in cooperation with Uppsala-based biotech company Vivolux AB, where Stig Linder is also a board member. A clinical study of the substance in collaboration with American researchers is planned to take place this year. The research has been funded by grants from the Swedish Cancer Society, the Cancer Research Foundations of Radiumhemmet, the Swedish Research Council, the Alex and Eva Wallström Foundation and Swedish Foundation for Strategic Research.


Story Source:

The above story is based on materials provided by Karolinska Institutet. Note: Materials may be edited for content and length.


Journal Reference:

  1. Xiaonan Zhang, Mårten Fryknäs, Emma Hernlund, Walid Fayad, Angelo De Milito, Maria Hägg Olofsson, Vladimir Gogvadze, Long Dang, Sven Påhlman, Leoni A. Kunz Schughart, Linda Rickardson, Padraig D′Arcy, Joachim Gullbo, Peter Nygren, Rolf Larsson, Stig Linder. Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nature Communications, 2014; 5 DOI: 10.1038/ncomms4295

Cite This Page:

Karolinska Institutet. "New drug candidate starves dormant cancer cells." ScienceDaily. ScienceDaily, 18 February 2014. <www.sciencedaily.com/releases/2014/02/140218114121.htm>.
Karolinska Institutet. (2014, February 18). New drug candidate starves dormant cancer cells. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2014/02/140218114121.htm
Karolinska Institutet. "New drug candidate starves dormant cancer cells." ScienceDaily. www.sciencedaily.com/releases/2014/02/140218114121.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) — The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) — An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) — Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
CDC Calls for New Ebola Safety Guidelines

CDC Calls for New Ebola Safety Guidelines

AP (Oct. 20, 2014) — Centers for Disease Control and Prevention Director Dr. Tom Frieden laid out new guidelines for health care workers when dealing with the deadly Ebola virus including new precautions when taking off personal protective equipment. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins